Group items tagged

What is this creative economy? It is an economic system that relies most on ideas to serve as its major capital, instead of services or physical capital. Take Google for example. In an economy based on ideas, the potentialfor breakaway successes like Google is far greater.

According to Richard Florida’s The Rise of the Creative Class: And How it’s Transforming Work, Leisure,Community and Everyday Life, members of the creative class are very different from those who are employed in the manufacturing, service or agriculture industries. They contribute to our economy primarily by producing the new forms and ideas exploited by our various industries and decision-makers.   What Florida terms the “super creative core” of this new class includes “scientists and engineers, university professors, poets and novelists, artists, entertainers, actors, designersand architects, as well as the ‘thought leadership’ of modern society: non-fiction writers, editors, cultural figures, think-tank researchers, analysts and other opinion-makers.”

What sets a creative city apart from a non-creative city? Florida proposes that it is the “three Ts of economic development”: technology, talent and tolerance.

"The size of what Quebec did caught our attention," says CVCA president Gregory Smith from the association's tiny office in Toronto's MaRS Centre, a renovated 1913 hospital now a facility to house tech startups.

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.

MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.

MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.

Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.

ore recently, Ontario's Poverty Reduction Strategy pledged $6-million to the Social Innovation Generation program at MaRS, established to provide social entrepreneurs with knowledge, contacts and capital.

Associations such as the Social Enterprise Council of Canada and the Causeway Social Finance Initiative are engaging civic and financial decision-makers to develop a more fostering environment for social enterprise.

The funding will include $100 million to establish the Operating Line of Credit Guarantee and $350 million over three years to help drive venture capital investment in promising Canadian technology businesses.

MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.

upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.

“MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”

MobileMonday Toronto and MaRS are delighted to announce a partnership to develop and host a range of dynamic events for the city’s mobile industry professionals. MobileMonday at MaRS will offer thought leadership and critical industry perspectives – most recently from a senior manager at Research in Motion – while connecting top-tier professionals and boosting the profile of one of the fastest-growing sectors of communications technology.

“MaRS is a fantastic environment for sharing ideas and industry knowledge, two key building blocks of the MobileMonday community,” said Jim Brown and Alexander S. Bosika, co-founders of the MobileMonday Toronto chapter. “MaRS and its network of business advisors and capital providers are also of great benefit to many of our members who are developing business plans and seeking capital.”

For MaRS, the partnership is a natural fit with great potential to benefit the hundreds of start-up clients from across Ontario who are working hard to turn their innovative concepts into viable, thriving businesses, and come to MaRS for advice and connections to potential customers and investors. 

New Biology Ventures is a life-sciences focused venture capital incubator.   We invest in early stage opportunities through the creation and maturation of start-up companies that focus on the development and commercialization of therapeutic biopharmaceuticals. We change the economics of drug development through our unique combination of expertise in finance and structuring companies along with the capability to efficiently and effectively commercialize drugs.